Citations (69)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Mingyang Wang, Xiaosheng Fang & Xin Wang. (2020) Emerging role of histone deacetylase inhibitors in the treatment of diffuse large B-cell lymphoma. Leukemia & Lymphoma 61:4, pages 763-775.
Read now
Read now
Yongping Zhou, Sijin Cheng, Sinuo Chen & Yongzhao Zhao. (2018) Prognostic and clinicopathological value of SIRT3 expression in various cancers: a systematic review and meta-analysis. OncoTargets and Therapy 11, pages 2157-2167.
Read now
Read now
Nidhi Tandon, Vijay Ramakrishnan & Shaji K Kumar. (2016) Clinical use and applications of histone deacetylase inhibitors in multiple myeloma. Clinical Pharmacology: Advances and Applications 8, pages 35-44.
Read now
Read now
Susmitha Apuri & Lubomir Sokol. (2016) An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin’s lymphoma. Expert Opinion on Investigational Drugs 25:6, pages 687-696.
Read now
Read now
Hui Yang, Sirisha Maddipoti, Andres Quesada, Zachary Bohannan, Monica Cabrero Calvo, Simona Colla, Yue Wei, Marcos Estecio, William Wierda, Carlos Bueso-Ramos & Guillermo Garcia-Manero. (2015) Analysis of class I and II histone deacetylase gene expression in human leukemia. Leukemia & Lymphoma 56:12, pages 3426-3433.
Read now
Read now
Shabir Ahmad Ganai, Shashwath Malli Kalladi & Vijayalakshmi Mahadevan. (2015) HDAC inhibition through valproic acid modulates the methylation profiles in human embryonic kidney cells. Journal of Biomolecular Structure and Dynamics 33:6, pages 1185-1197.
Read now
Read now
Sridurga Mithraprabhu, Anna Kalff, Annie Chow, Tiffany Khong & Andrew Spencer. (2014) Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma. Epigenetics 9:11, pages 1511-1520.
Read now
Read now
Michaël Van Damme, Emerence Crompot, Nathalie Meuleman, Philippe Mineur, Barbara Dessars, Hakim El Housni, Dominique Bron, Laurence Lagneaux & Basile Stamatopoulos. (2014) Global histone deacetylase enzymatic activity is an independent prognostic marker associated with a shorter overall survival in chronic lymphocytic leukemia patients. Epigenetics 9:10, pages 1374-1381.
Read now
Read now
Lorena Rosik, Günter Niegisch, Ute Fischer, Manfred Jung, Wolfgang Arthur Schulz & Michèle Janine Hoffmann. (2014) Limited efficacy of specific HDAC6 inhibition in urothelial cancer cells. Cancer Biology & Therapy 15:6, pages 742-757.
Read now
Read now
Articles from other publishers (60)
Jingjing Pu, Amit Sharma, Jian Hou & Ingo GH Schmidt-Wolf. (2023) Histone deacetylase 6: at the interface of cancer and neurodegeneration. Epigenomics.
Crossref
Crossref
LongJiang DI, Jun ZHANG & Wei-Guo ZHU. (2023) Progress in the research of epigenetic regulators in cancer therapy. SCIENTIA SINICA Vitae 53:11, pages 1546-1563.
Crossref
Crossref
Yun Deng, Qian Cheng & Jing He. (2023) HDAC inhibitors: Promising agents for leukemia treatment. Biochemical and Biophysical Research Communications 680, pages 61-72.
Crossref
Crossref
Yizhuo Wang, Rishika Abrol, Jeffrey Y. W. Mak, Kaustav Das Gupta, Divya Ramnath, Denuja Karunakaran, David P. Fairlie & Matthew J. Sweet. (2022) Histone deacetylase 7: a signalling hub controlling development, inflammation, metabolism and disease. The FEBS Journal 290:11, pages 2805-2832.
Crossref
Crossref
Francisco Alejandro Lagunas-Rangel. (2023) Role of SIRT5 in cancer. Friend or Foe?. Biochimie 209, pages 131-141.
Crossref
Crossref
João Vitor Caetano Goes, Luiz Gustavo Carvalho, Roberta Taiane Germano de Oliveira, Mayara Magna de Lima Melo, Lázaro Antônio Campanha Novaes, Daniel Antunes Moreno, Paola Gyuliane Gonçalves, Carlos Victor Montefusco-Pereira, Ronald Feitosa Pinheiro & Howard Lopes Ribeiro Junior. (2022) Role of Sirtuins in the Pathobiology of Onco-Hematological Diseases: A PROSPERO-Registered Study and In Silico Analysis. Cancers 14:19, pages 4611.
Crossref
Crossref
Stefano Federico, Tuhina Khan, Anna Fontana, Simone Brogi, Rosaria Benedetti, Federica Sarno, Gabriele Carullo, Alex Pezzotta, Akella Prasanth Saraswati, Eugenia Passaro, Luca Pozzetti, Alessandro Papa, Nicola Relitti, Sandra Gemma, Stefania Butini, Anna Pistocchi, Anna Ramunno, Fabrizio Vincenzi, Katia Varani, Vanessa Tatangelo, Laura Patrussi, Cosima T. Baldari, Simona Saponara, Beatrice Gorelli, Stefania Lamponi, Massimo Valoti, Fulvio Saccoccia, Marialaura Giannaccari, Giovina Ruberti, Daniel Herp, Manfred Jung, Lucia Altucci & Giuseppe Campiani. (2022) Azetidin-2-one-based small molecules as dual hHDAC6/HDAC8 inhibitors: Investigation of their mechanism of action and impact of dual inhibition profile on cell viability. European Journal of Medicinal Chemistry 238, pages 114409.
Crossref
Crossref
Amit Jaiswal, Zhu Xudong, Ju Zhenyu & Gabriele Saretzki. (2021) Mitochondrial sirtuins in stem cells and cancer. The FEBS Journal 289:12, pages 3393-3415.
Crossref
Crossref
Paloma García-Martín, Ana Moñiz Díez, José Manuel Sánchez Maldonado, Antonio José Cabrera Serrano, Rob ter Horst, Yolanda Benavente, Stefano Landi, Angelica Macauda, Alyssa Clay-Gilmour, Francisca Hernández-Mohedo, Yasmeen Niazi, Pedro González-Sierra, Blanca Espinet, Juan José Rodríguez-Sevilla, Rossana Maffei, Gonzalo Blanco, Matteo Giaccherini, Anna Puiggros, James Cerhan, Roberto Marasca, Marisa Cañadas-Garre, Miguel Ángel López-Nevot, Tzu Chen-Liang, Hauke Thomsen, Irene Gámez, Víctor Moreno, Rafael Marcos-Gragera, María García-Álvarez, Javier Llorca, Andrés Jerez, Sonja Berndt, Aleksandra Butrym, Aaron D. Norman, Delphine Casabonne, Mario Luppi, Susan L. Slager, Kari Hemminki, Yang Li, Miguel Alcoceba, Daniele Campa, Federico Canzian, Silvia de Sanjosé, Asta Försti, Mihai G. Netea, Manuel Jurado & Juan Sainz. (2022) Validation and functional characterization of GWAS-identified variants for chronic lymphocytic leukemia: a CRuCIAL study. Blood Cancer Journal 12:5.
Crossref
Crossref
Wenxiu Zhao, Xiaobin Jiang, Karrin Weisenthal, Jun Ma, Erin M. Botticelli, Yunli Zhou, E. Tessa Hedley-Whyte, Baiyao Wang, Brooke Swearingen, Roy J. Soberman, Anne Klibanski & Xun Zhang. (2022) High Histone Deacetylase 2/3 Expression in Non-Functioning Pituitary Tumors. Frontiers in Oncology 12.
Crossref
Crossref
Patrik Zeyen, Yanira Zeyn, Daniel Herp, Fereshteh Mahmoudi, Talha Z. Yesiloglu, Frank Erdmann, Matthias Schmidt, Dina Robaa, Christophe Romier, Johannes Ridinger, Corey J. Herbst-Gervasoni, David W. Christianson, Ina Oehme, Manfred Jung, Oliver H. Krämer & Wolfgang Sippl. (2022) Identification of histone deacetylase 10 (HDAC10) inhibitors that modulate autophagy in transformed cells. European Journal of Medicinal Chemistry 234, pages 114272.
Crossref
Crossref
Sina Dalvand, Amin Namdari, Farzad Sepahvand, Mohammad Hassan Meshkibaf & GholamReza Ahmadpour. (2021) Investigation of Decitabine Effects on HDAC3 and HDAC7 mRNA Expression in NALM-6 and HL-60 Cancer Cell Lines. Reports of Biochemistry and Molecular Biology 10:3, pages 420-428.
Crossref
Crossref
Mahdieh Mehrpouri, Atieh Pourbagheri-Sigaroodi & Davood Bashash. (2021) The contributory roles of histone deacetylases (HDACs) in hematopoiesis regulation and possibilities for pharmacologic interventions in hematologic malignancies. International Immunopharmacology 100, pages 108114.
Crossref
Crossref
Fajuan Cheng, Bin Zheng, Jianwei Wang, Guiting Zhao, Zhongshun Yao, Zhihong Niu & Wei He. (2021) Histone deacetylase 10, a potential epigenetic target for therapy. Bioscience Reports 41:6.
Crossref
Crossref
Kenneth K.W. To & William C.S. Cho. (2021) Flavonoids Overcome Drug Resistance to Cancer Chemotherapy by Epigenetically Modulating Multiple Mechanisms. Current Cancer Drug Targets 21:4, pages 289-305.
Crossref
Crossref
Carmela Dell’Aversana, Cristina Giorgio, Francesco Paolo Tambaro, Giulia Sgueglia & Lucia Altucci. 2021. Medical Epigenetics. Medical Epigenetics
447
469
.
Ryan A. Denu. 2021. Sirtuin Biology in Cancer and Metabolic Disease. Sirtuin Biology in Cancer and Metabolic Disease
233
258
.
Lulu Liu, Jingjing Zhang, Xianning Zhang, Panpan Cheng, Lei Liu, Qian Huang, Haihui Liu, Saisai Ren, Peng Wei, Cuiling Wang, Cuiyun Dou, Lulu Chen, Xin Liu, Hao Zhang & Mingtai Chen. (2020) HMGB1: an important regulator of myeloid differentiation and acute myeloid leukemia as well as a promising therapeutic target. Journal of Molecular Medicine 99:1, pages 107-118.
Crossref
Crossref
Attila Csala, Aeilko H. Zwinderman & Michel H. Hof. (2020) Multiset sparse partial least squares path modeling for high dimensional omics data analysis. BMC Bioinformatics 21:1.
Crossref
Crossref
Zhihua Wang, Yang Zhang, Shicong Zhu, Hongling Peng, Yongheng Chen, Zhao Cheng, Sufang Liu, Yunya Luo, Ruijuan Li, Mingyang Deng, Yunxiao Xu, Guoyu Hu, Lin Chen & Guangsen Zhang. (2020) A small molecular compound CC1007 induces cross-lineage differentiation by inhibiting HDAC7 expression and HDAC7/MEF2C interaction in BCR-ABL1− pre-B-ALL. Cell Death & Disease 11:9.
Crossref
Crossref
Nina Kreuzberger, Johanna AAG Damen, Marialena Trivella, Lise J Estcourt, Angela Aldin, Lisa Umlauff, Maria DLA Vazquez-Montes, Robert Wolff, Karel GM Moons, Ina Monsef, Farid Foroutan, Karl-Anton Kreuzer & Nicole Skoetz. (2020) Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis. Cochrane Database of Systematic Reviews 2020:7.
Crossref
Crossref
Pengfei Shi, Min Zhou & Yonggang Yang. (2019) Upregulated tumor sirtuin 2 expression correlates with reduced TNM stage and better overall survival in surgical breast cancer patients. Irish Journal of Medical Science (1971 -) 189:1, pages 83-89.
Crossref
Crossref
Zhen Zhou, Qin Fang, Peifan Li, Dan Ma, Nana Zhe, Mei Ren, Bingqing Chen, Zhengchang He, Jun Wang, Qin Zhong & Jishi Wang. (2019) Entinostat combined with Fludarabine synergistically enhances the induction of apoptosis in TP53 mutated CLL cells via the HDAC1/HO-1 pathway. Life Sciences 232, pages 116583.
Crossref
Crossref
Shahrzad Movafagh & Amanda Munson. 2019. Epigenetics of Cancer Prevention. Epigenetics of Cancer Prevention
75
105
.
Kamira Maharaj, John J. PowersAlex AchilleSusan DengRenee FonsecaMibel Pabon-SaldanaSteven N. QuayleSimon S. JonesAlejandro Villagra, Eduardo M. Sotomayor, Eva Sahakian & Javier Pinilla-Ibarz. (2018) Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia. Blood Advances 2:21, pages 3012-3024.
Crossref
Crossref
Jinlin Cao, Wang Lv, Luming Wang, Jinming Xu, Ping Yuan, Sha Huang, Zhehao He & Jian Hu. (2018) Ricolinostat (ACY-1215) suppresses proliferation and promotes apoptosis in esophageal squamous cell carcinoma via miR-30d/PI3K/AKT/mTOR and ERK pathways. Cell Death & Disease 9:8.
Crossref
Crossref
Peng-Chan Lin, Hao-Yu Hsieh, Po-Chen Chu & Ching Chen. (2018) Therapeutic Opportunities of Targeting Histone Deacetylase Isoforms to Eradicate Cancer Stem Cells. International Journal of Molecular Sciences 19:7, pages 1939.
Crossref
Crossref
Harvey E. Johnston, Matthew J. Carter, Marta Larrayoz, James Clarke, Spiro D. Garbis, David Oscier, Jonathan C. Strefford, Andrew J. Steele, Renata Walewska & Mark S. Cragg. (2018) Proteomics Profiling of CLL Versus Healthy B-cells Identifies Putative Therapeutic Targets and a Subtype-independent Signature of Spliceosome Dysregulation. Molecular & Cellular Proteomics 17:4, pages 776-791.
Crossref
Crossref
Manon Lernoux, Michael Schnekenburger, Mario Dicato & Marc Diederich. (2018) Anti-cancer effects of naturally derived compounds targeting histone deacetylase 6-related pathways. Pharmacological Research 129, pages 337-356.
Crossref
Crossref
Amir Hosseini & Saverio Minucci. 2018. Epigenetics in Human Disease. Epigenetics in Human Disease
141
217
.
Malgorzata BobrowiczMichal DwojakBeata Pyrzynska, Joanna StachuraAngelika Muchowicz, Elise BerthelNicole Dalla-VeneziaMieszko KozikowskiMarta SiernickaNina Miazek, Piotr Zapala, Antoni Domagala, Kamil Bojarczuk, Agata MalendaJoanna BarankiewiczAgnieszka Graczyk-Jarzynka, Agnieszka Zagozdzon, Magdalena Gabrysiak, Jean-Jacques DiazMarta KarpEwa Lech-MarandaMalgorzata Firczuk, Krzysztof GiannopoulosDimitar G. Efremov, Luca LaurentiDunja BaatoutLukas FrenzelAgata MalinowskaMikolaj SlabickiThorsten Zenz, Abdessamad Zerrouqi, Jakub Golab & Magdalena Winiarska. (2017) HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies. Blood 130:14, pages 1628-1638.
Crossref
Crossref
Zsuzsanna Ga?l, ?va Ol?h, L?szl? Rejt?Ferenc Erd?di & L?szl? Csernoch. (2016) Strong Correlation between the Expression Levels of HDAC4 and SIRT6 in Hematological Malignancies of the Adults. Pathology & Oncology Research 23:3, pages 493-504.
Crossref
Crossref
A E Witt, C-W Lee, T I Lee, D J Azzam, B Wang, C Caslini, F Petrocca, J Grosso, M Jones, E B Cohick, A B Gropper, C Wahlestedt, A L Richardson, R Shiekhattar, R A Young & T A Ince. (2016) Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer. Oncogene 36:12, pages 1707-1720.
Crossref
Crossref
Ola Al-Sanabra, Andrew D. Duckworth, Mark A. Glenn, Benjamin R. B. Brown, Piera Angelillo, Kelvin Lee, John Herbert, Francesco Falciani, Nagesh Kalakonda & Joseph R. Slupsky. (2017) Transcriptional mechanism of vascular endothelial growth factor-induced expression of protein kinase CβII in chronic lymphocytic leukaemia cells. Scientific Reports 7:1.
Crossref
Crossref
Michaël Van Damme, Emerence Crompot, Nathalie Meuleman, Marie Maerevoet, Philippe Mineur, Dominique Bron, Laurence Lagneaux & Basile Stamatopoulos. (2016) Characterization of TET and IDH gene expression in chronic lymphocytic leukemia: comparison with normal B cells and prognostic significance. Clinical Epigenetics 8:1.
Crossref
Crossref
Rui Su, Jia-Nan Gong, Ming-Tai Chen, Li Song, Chao Shen, Xin-Hua Zhang, Xiao-Lin Yin, Hong-Mei Ning, Bing Liu, Fang Wang, Yan-Ni Ma, Hua-Lu Zhao, Jia Yu & Jun-Wu Zhang. (2016) c-Myc suppresses miR-451⊣YWTAZ/AKT axis via recruiting HDAC3 in acute myeloid leukemia. Oncotarget 7:47, pages 77430-77443.
Crossref
Crossref
Weiwei Qi, Li Yan, Chunyan Liu, Rong Fu, Huaquan Wang & Zonghong Shao. (2016) Abnormal histone acetylation of CD8+ T cells in patients with severe aplastic anemia. International Journal of Hematology 104:5, pages 540-547.
Crossref
Crossref
Yixuan Li & Edward Seto. (2016) HDACs and HDAC Inhibitors in Cancer Development and Therapy. Cold Spring Harbor Perspectives in Medicine 6:10, pages a026831.
Crossref
Crossref
Margherita Brindisi, Caterina Cavella, Simone Brogi, Angela Nebbioso, Johanna Senger, Samuele Maramai, Alfonso Ciotta, Concetta Iside, Stefania Butini, Stefania Lamponi, Ettore Novellino, Lucia Altucci, Manfred Jung, Giuseppe Campiani & Sandra Gemma. (2016) Phenylpyrrole-based HDAC inhibitors: synthesis, molecular modeling and biological studies. Future Medicinal Chemistry 8:13, pages 1573-1587.
Crossref
Crossref
Melanie Gertz & Clemens Steegborn. (2016) Using mitochondrial sirtuins as drug targets: disease implications and available compounds. Cellular and Molecular Life Sciences 73:15, pages 2871-2896.
Crossref
Crossref
Ailing Deng, Qiaoyang Ning, Lei Zhou & Yaojie Liang. (2016) SIRT2 is an unfavorable prognostic biomarker in patients with acute myeloid leukemia. Scientific Reports 6:1.
Crossref
Crossref
Wei Yu, Ryan A. Denu, Kimberly A. Krautkramer, Kreg M. Grindle, David T. Yang, Fotis Asimakopoulos, Peiman Hematti & John M. Denu. (2016) Loss of SIRT3 Provides Growth Advantage for B Cell Malignancies. Journal of Biological Chemistry 291:7, pages 3268-3279.
Crossref
Crossref
Galit Pinto, Biana Shtaif, Moshe Phillip & Galia Gat-Yablonski. (2016) Growth attenuation is associated with histone deacetylase 10-induced autophagy in the liver. The Journal of Nutritional Biochemistry 27, pages 171-180.
Crossref
Crossref
C. Giorgio, C. Dell'Aversana & L. Altucci. 2016. Medical Epigenetics. Medical Epigenetics
483
498
.
Jun Lu, Yan-Fang Tao, Zhi-Heng Li, Lan Cao, Shao-Yan Hu, Na-Na Wang, Xiao-Juan Du, Li-Chao Sun, Wen-Li Zhao, Pei-Fang Xiao, Fang Fang, Li-xiao Xu, Yan-Hong Li, Gang Li, He Zhao, Jian Ni, Jian Wang, Xing Feng & Jian Pan. (2015) Analyzing the gene expression profile of anaplastic histology Wilms’ tumor with real-time polymerase chain reaction arrays. Cancer Cell International 15:1.
Crossref
Crossref
Daniel Vitt, Roland Baumgartner & Hella Kohlhof. 2015. Epigenetics for Drug Discovery. Epigenetics for Drug Discovery
96
126
.
Susana Junqueira-Neto, Filipa Q. Vieira, Diana Montezuma, Natália R. Costa, Luís Antunes, Tiago Baptista, Ana Isabel Oliveira, Inês Graça, Ângelo Rodrigues, José S. Magalhães, Jorge Oliveira, Rui Henrique & Carmen Jerónimo. (2015) Phenotypic impact of deregulated expression of class I histone deacetylases in urothelial cell carcinoma of the bladder. Molecular Carcinogenesis 54:7, pages 523-531.
Crossref
Crossref
Leila Haery, Ryan C. Thompson & Thomas D. Gilmore. (2015) Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancy. Genes & Cancer 6:5-6, pages 184-213.
Crossref
Crossref
Emerence Crompot, Michael Van Damme, Hugues Duvillier, Karlien Pieters, Marjorie Vermeesch, David Perez-Morga, Nathalie Meuleman, Philippe Mineur, Dominique Bron, Laurence Lagneaux & Basile Stamatopoulos. (2015) Avoiding False Positive Antigen Detection by Flow Cytometry on Blood Cell Derived Microparticles: The Importance of an Appropriate Negative Control. PLOS ONE 10:5, pages e0127209.
Crossref
Crossref
Emily Koeneke, Olaf Witt & Ina Oehme. (2015) HDAC Family Members Intertwined in the Regulation of Autophagy: A Druggable Vulnerability in Aggressive Tumor Entities. Cells 4:2, pages 135-168.
Crossref
Crossref
Kang Lu, Xiao-sheng Fang, Li-li Feng, Yu-jie Jiang, Xiang-xiang Zhou, Xin Liu, Pei-pei Li, Na Chen, Mei Ding, Na Wang, Jie Zhang & Xin Wang. (2015) The STAT3 inhibitor WP1066 reverses the resistance of chronic lymphocytic leukemia cells to histone deacetylase inhibitors induced by interleukin-6. Cancer Letters 359:2, pages 250-258.
Crossref
Crossref
B Barneda-Zahonero, O Collazo, A Azagra, I Fernández-Duran, J Serra-Musach, A B M M K Islam, N Vega-García, R Malatesta, M Camós, A Gómez, L Román-González, A Vidal, N López-Bigas, A Villanueva, M Esteller & M Parra. (2015) The transcriptional repressor HDAC7 promotes apoptosis and c-Myc downregulation in particular types of leukemia and lymphoma. Cell Death & Disease 6:2, pages e1635-e1635.
Crossref
Crossref
Carole Seidel, Michael Schnekenburger, Mario Dicato & Marc Diederich. (2015) Histone deacetylase 6 in health and disease. Epigenomics 7:1, pages 103-118.
Crossref
Crossref
Claudia V. Andreu-Vieyra & James R. Berenson. (2014) The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma. Therapeutic Advances in Hematology 5:6, pages 197-210.
Crossref
Crossref
Oliver H. Kr?mer, Siavosh Mahboobi & Andreas Sellmer. (2014) Drugging the HDAC6?HSP90 interplay in malignant cells. Trends in Pharmacological Sciences 35:10, pages 501-509.
Crossref
Crossref
S Kasar, C Underbayev, Y Yuan, M Hanlon, S Aly, H Khan, V Chang, M Batish, T Gavrilova, F Badiane, H Degheidy, G Marti & E Raveche. (2013) Therapeutic implications of activation of the host gene (Dleu2) promoter for miR-15a/16-1 in chronic lymphocytic leukemia. Oncogene 33:25, pages 3307-3315.
Crossref
Crossref
Xiaoyang Li, Elizabeth S. Inks, Xiaoguang Li, Jinning Hou, C. James Chou, Jian Zhang, Yuqi Jiang, Yingjie Zhang & Wenfang Xu. (2014)
Discovery of the First
N
-Hydroxycinnamamide-Based Histone Deacetylase 1/3 Dual Inhibitors with Potent Oral Antitumor Activity
. Journal of Medicinal Chemistry 57:8, pages 3324-3341.
Crossref
Crossref
Soraya E Gutierrez & Francisco A Romero-Oliva. (2013) Epigenetic changes: a common theme in acute myelogenous leukemogenesis. Journal of Hematology & Oncology 6:1.
Crossref
Crossref
Gwen Jordaan, Wei Liao & Sanjai Sharma. (2013) E-cadherin gene re-expression in chronic lymphocytic leukemia cells by HDAC inhibitors. BMC Cancer 13:1.
Crossref
Crossref
Stephanie F. MacCallum, Michael J. Groves, John James, Karen Murray, Virginia Appleyard, Alan R. Prescott, Abed A. Drbal, Anna Nicolaou, Joan Cunningham, Sally Haydock, Ian G. Ganley, Nicholas J. Westwood, Philip J. Coates, Sonia Lain & Sudhir Tauro. (2013) Dysregulation of autophagy in chronic lymphocytic leukemia with the small-molecule Sirtuin inhibitor Tenovin-6. Scientific Reports 3:1.
Crossref
Crossref